Evidence map›Paper›PMID 36699147›Full record

ReviewMedicine international

Ameliorative effect of taurine against diabetes and renal-associated disorders (Review).

Stella Baliou, Maria Adamaki, Petros Ioannou, Aglaia Pappa, Mihalis I Panayiotidis, Ioannis Christodoulou, Demetrios A Spandidos, Anthony M Kyriakopoulos, Vassilis Zoumpourlis

Open access · hybridAbstract readReview
In one paragraph

Review in Medicine international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Stella BaliouInstitute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.
Maria AdamakiInstitute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.
Petros IoannouDepartment of Internal Medicine and Infectious Diseases, University Hospital of Heraklion, 71110 Heraklion, Greece.
Aglaia PappaDepartment of Molecular Biology and Genetics, Faculty of Health Sciences, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Mihalis I PanayiotidisDepartment of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology and Genetics, 2371 Nicosia, Cyprus.
Ioannis ChristodoulouInstitute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.
Demetrios A SpandidosLaboratory of Clinical Virology, Medical School, University of Crete, 71409 Heraklion, Greece.
Anthony M KyriakopoulosNasco AD Biotechnology Laboratory, 18536 Piraeus, Greece.
Vassilis ZoumpourlisInstitute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.
National Hellenic Research Foundation · GRCyprus Institute of Neurology and Genetics · CYDemocritus University of Thrace · GRUniversity Hospital of Heraklion · GRUniversity of Crete · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To develop novel therapeutic methods for both diabetic and renal disorders, scientists had initially focused on elucidating the molecular mechanisms of taurine in established cell lines and mouse models. Although a large amount of data have been revealed, taurine has been confirmed to be the next step of novel promising therapeutic interventions against diabetic disorders. Taurine appears to ameliorate diabetes 1-related complications in various organs through its antioxidant, anti-inflammatory and anti-hormonal actions. In type 2 diabetes, taurine has been positively implicated in glucose homeostasis, exerting potent hypoglycemic, anti-obesity, hypotensive and hypolipidemic effects. Of particular interest is that taurine provides protection against renal dysfunction, including hypertension and proteinuria, specific glomerular and tubular disorders, acute and chronic renal conditions, and diabetic nephropathy. The ameliorative effects of taurine against renal disorders are based on its osmoregulatory properties, its association with signaling pathways and its association with the renin-angiotensin-aldosterone system (RAAS). Further clinical studies are required to ensure the importance of research findings.

Indexed as

diabetesdiabetic nephropathyrenal transplantationtaurine

Identifiers

PMID36699147
PMCPMC9855276
OpenAlexW3172681547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.